Axsome Therapeutics Inc [AXSM] stock is trading at $82.42, up 1.28%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AXSM shares have gain 4.41% over the last week, with a monthly amount drifted -8.45%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference. In a post published today on Yahoo Finance, Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, from 9:50-10:20 a.m. Eastern Time at the Marriott Copley Place in Boston, Massachusetts.
From an analyst’s perspective:
Axsome Therapeutics Inc [NASDAQ: AXSM] stock has seen the most recent analyst activity on February 06, 2024, when UBS initiated its Buy rating and assigned the stock a price target of $111. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on January 25, 2024, and set its price target to $126. On December 13, 2023, Citigroup initiated with a Buy rating and assigned a price target of $125 on the stock. BofA Securities upgraded its rating to a Neutral and increased its price target to $81 on August 08, 2023. Piper Sandler initiated its recommendation with a Neutral and recommended $75 as its price target on January 05, 2023. Loop Capital started tracking with a Buy rating for this stock on November 01, 2022, and assigned it a price target of $95.
Axsome Therapeutics Inc [AXSM] stock has fluctuated between $53.71 and $98.40 over the past year. Currently, Wall Street analysts expect the stock to reach $81 within the next 12 months. Axsome Therapeutics Inc [NASDAQ: AXSM] shares were valued at $82.42 at the most recent close of the market. An investor can expect a potential drop of -1.72% based on the average AXSM price forecast.
Analyzing the AXSM fundamentals
Axsome Therapeutics Inc [NASDAQ:AXSM] reported sales of 270.60M for the trailing twelve months, which represents a growth of 193.50%. Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -0.86%, Pretax Profit Margin comes in at -0.88%, and Net Profit Margin reading is -0.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.41, Equity is -1.12 and Total Capital is -0.52. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 80.95 points at the first support level, and at 79.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 84.00, and for the 2nd resistance point, it is at 85.59.
Axsome Therapeutics Inc [AXSM] reported earnings per share of -$2.08 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.17/share, meaning a difference of -$0.91 and a surprise factor of -77.80%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.32 per share as compared to estimates of -$1.2 per share, a difference of -$0.12 representing a surprise of -10.00%.
Ratios To Look Out For
For context, Axsome Therapeutics Inc’s Current Ratio is 3.63. In addition, the Quick Ratio stands at 3.52 and the Cash Ratio stands at 2.78. Considering the valuation of this stock, the price to sales ratio is 14.43, the price to book ratio is 20.44.
Transactions by insiders
Recent insider trading involved Coleman Mark, Director, that happened on Sep 15 when 18572.0 shares were sold. Director, Coleman Mark completed a deal on Sep 15 to sell 11016.0 shares.
